tiprankstipranks
Advertisement
Advertisement

PCBIO1R Stock Latest News

NOBO Medicine Positions BTK Inhibitor Poseltinib for Rare Lymphoma Amid Immune Aging Focus
Private CompaniesNOBO Medicine Positions BTK Inhibitor Poseltinib for Rare Lymphoma Amid Immune Aging Focus
2d ago
BIO1R
NOBO Medicine Refocuses Pipeline on Immune Aging and BTK Inhibitor Development
PremiumPrivate Companies
NOBO Medicine Refocuses Pipeline on Immune Aging and BTK Inhibitor Development
2d ago
BIO1R
Novartis Targets Next-Generation IgE Therapy With $2 Billion Excellergy Deal
PremiumPrivate Companies
Novartis Targets Next-Generation IgE Therapy With $2 Billion Excellergy Deal
8d ago
BIO1R
Novartis Targets Next-Generation IgE Therapy With $2 Billion Excellergy Acquisition
PremiumPrivate Companies
Novartis Targets Next-Generation IgE Therapy With $2 Billion Excellergy Acquisition
9d ago
BIO1R
Gastric Cancer Bispecific Givastomig Moves Toward Accelerated Approval Pathway
PremiumPrivate Companies
Gastric Cancer Bispecific Givastomig Moves Toward Accelerated Approval Pathway
22d ago
BIO1R
ABL Bio Partnered CLDN18.2 Bispecific Advances Toward Potential Registrational Phase 3 in Gastric Cancer
PremiumPrivate CompaniesABL Bio Partnered CLDN18.2 Bispecific Advances Toward Potential Registrational Phase 3 in Gastric Cancer
22d ago
BIO1R
AI Imaging Firm Lunit Targets Broader Breast Cancer Screening Platform Play
Premium
Private Companies
AI Imaging Firm Lunit Targets Broader Breast Cancer Screening Platform Play
23d ago
BIO1R
Lunit Targets Dominant Platform Role in U.S. Breast Cancer Screening Market
Premium
Private Companies
Lunit Targets Dominant Platform Role in U.S. Breast Cancer Screening Market
23d ago
BIO1R
Roche’s Giredestrant Setback Clouds Outlook in Next-Generation SERD Race
PremiumPrivate Companies
Roche’s Giredestrant Setback Clouds Outlook in Next-Generation SERD Race
28d ago
BIO1R
Roche SERD Setback Raises Questions Over Giredestrant Breast Cancer Potential
PremiumPrivate Companies
Roche SERD Setback Raises Questions Over Giredestrant Breast Cancer Potential
28d ago
BIO1R
IMBiologics Targets 2027 PoC Milestone and Pipeline Expansion in Hidradenitis Suppurativa
PremiumPrivate Companies
IMBiologics Targets 2027 PoC Milestone and Pipeline Expansion in Hidradenitis Suppurativa
1M ago
BIO1R
IMBiologics Targets 2027 Phase 2 PoC as Potential Catalyst in Hidradenitis Suppurativa
PremiumPrivate Companies
IMBiologics Targets 2027 Phase 2 PoC as Potential Catalyst in Hidradenitis Suppurativa
1M ago
BIO1R
Korean Biotech 카나프 Targets Multiple IND Filings and Explores Global AMD Licensing
PremiumPrivate CompaniesKorean Biotech 카나프 Targets Multiple IND Filings and Explores Global AMD Licensing
1M ago
BIO1R
Henlius Expands Clinical Program for AC101 HER2 Antibody in Breast Cancer
Premium
Private Companies
Henlius Expands Clinical Program for AC101 HER2 Antibody in Breast Cancer
1M ago
BIO1R
CanaF Targets Multiple Oncology INDs and Explores Global Licensing for AMD Therapy
Premium
Private Companies
CanaF Targets Multiple Oncology INDs and Explores Global Licensing for AMD Therapy
1M ago
BIO1R
Henlius Expands Clinical Development of AbClon-Derived HER2 Antibody AC101 in Breast Cancer
PremiumPrivate Companies
Henlius Expands Clinical Development of AbClon-Derived HER2 Antibody AC101 in Breast Cancer
1M ago
BIO1R
Emerging Triple Agonist Data Underscore Intensifying Obesity Drug Race
PremiumPrivate Companies
Emerging Triple Agonist Data Underscore Intensifying Obesity Drug Race
1M ago
BIO1R
BreezeBio Raises Pre-IPO Funding and Positions Lead Type 1 Diabetes Program
PremiumPrivate Companies
BreezeBio Raises Pre-IPO Funding and Positions Lead Type 1 Diabetes Program
1M ago
BIO1R
Triple Agonist Obesity Therapies Face Intensifying Race as New Phase 2 Data Emerge
PremiumPrivate Companies
Triple Agonist Obesity Therapies Face Intensifying Race as New Phase 2 Data Emerge
1M ago
BIO1R
BreezeBio Pre-IPO Funding and Pipeline Progress Signal Shift to Clinical-Stage Biotech
PremiumPrivate CompaniesBreezeBio Pre-IPO Funding and Pipeline Progress Signal Shift to Clinical-Stage Biotech
1M ago
BIO1R
Triple Agonist Obesity Drug Data Underscore Competitive Pressure in GLP-1 Field
Premium
Private Companies
Triple Agonist Obesity Drug Data Underscore Competitive Pressure in GLP-1 Field
1M ago
BIO1R
BreezeBio Completes $25 Million Pre-IPO Round and Positions Lead Diabetes Program
Premium
Private Companies
BreezeBio Completes $25 Million Pre-IPO Round and Positions Lead Diabetes Program
1M ago
BIO1R

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >